Aileron Therapeutics, Inc. (ALRN)

NASDAQ: ALRN · IEX Real-Time Price · USD
0.195
-0.009 (-4.27%)
Sep 27, 2022 3:54 PM EDT - Market closed
-4.27%
Market Cap 17.71M
Revenue (ttm) n/a
Net Income (ttm) -29.92M
Shares Out 90.82M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 343,515
Open 0.201
Previous Close 0.204
Day's Range 0.190 - 0.202
52-Week Range 0.131 - 1.080
Beta 2.27
Analysts Buy
Price Target 2.04 (+946.2%)
Earnings Date Nov 10, 2022

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in pa... [Read more...]

Industry Biotechnology
IPO Date Jun 29, 2017
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ALRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ALRN stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 946.15% from the latest price.

Price Target
$2.04
(946.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

5 days ago - GlobeNewsWire

Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

3 weeks ago - GlobeNewsWire

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients...

1 month ago - GlobeNewsWire

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients wi...

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients...

1 month ago - GlobeNewsWire

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients...

2 months ago - GlobeNewsWire

Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

Aileron Therapeutics (NASDAQ: ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with firs...

2 months ago - Benzinga

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mut...

BOSTON, June 29, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients...

2 months ago - GlobeNewsWire

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neo...

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients'...

4 months ago - GlobeNewsWire

3 Oversold Biotech Stocks to Buy Now

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

Other symbols: NVAXVTVT
4 months ago - InvestorPlace

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients'...

4 months ago - GlobeNewsWire

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients'...

4 months ago - GlobeNewsWire

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected...

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients'...

4 months ago - GlobeNewsWire

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients'...

4 months ago - GlobeNewsWire

Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?

Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Cl...

BOSTON, April 21, 2022 (GLOBE NEWSWIRE) --  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

5 months ago - GlobeNewsWire

Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?

Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

BOSTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more ...

5 months ago - GlobeNewsWire

Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective...

6 months ago - GlobeNewsWire

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective t...

8 months ago - GlobeNewsWire

Aileron Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients...

8 months ago - GlobeNewsWire

Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a member ...

9 months ago - GlobeNewsWire

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients,...

10 months ago - GlobeNewsWire

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as R...

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's acti...

11 months ago - GlobeNewsWire

Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conferen...

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patient...

11 months ago - GlobeNewsWire

Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent

Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology ( ESMO21 ) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.  Aileron is devel...

1 year ago - Benzinga